476060.KQ
Onconic Therapeutics
KOE · Healthcare · Biotechnology · KR
KRW 17,110.00
+1.85%Year over year
Reported trailing growth
- Revenue
- +179.3%
- EBITDA
- +575.1%
- EBIT
- +913.4%
- EPS
- +70.1%
- Free cash flow
- +489.0%
- Operating cash flow
- +522.1%
Forward estimates
Based on analyst estimates
- Revenue
- -18.5%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +725.2%
- EBITDA
- +113.0%
- EBIT
- +137.8%
- Net income
- +206.3%
- EPS
- +11.0%
- Free cash flow
- +92.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026